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Abstract The matricellular protein connective tissue
growth factor (CCN2) is considered a faithful marker of
fibroblast activation in wound healing and in fibrosis.
CCN2 is induced during activation of hepatic stellate cells
(HSC). Here, we investigate the molecular basis of CCN2
gene expression in HSC. Fluoroscence activated cell sorting
was used to investigate CCN2 expression in HSC in vivo in
mice treated with CCl4. CCN2 and TGF-β mRNA
expression were assessed by polymerase chain reaction as
a function of culture-induced activation of HSC. CCN2
promoter/reporter constructs were used to map cis-acting
elements required for basal and TGFβ-induced CCN2
promoter activity. Real-time polymerase chain reaction
analysis was used to further clarify signaling pathways
required for CCN2 expression in HSC. CCl4 administration
in vivo increased CCN2 production by HSC. In vitro,
expression of CCN2 and TGF-β mRNA were concommi-
tantly increased in mouse HSC between days 0 and 14 of
culture. TGFβ-induced CCN2 promoter activity required
the Smad and Ets-1 elements in the CCN2 promoter and
was reduced by TGFβ type I receptor (ALK4/5/7)
inhibition. CCN2 overexpression in activated HSC was
ALK4/5/7-dependent. As CCN2 overexpression is a faith-
ful marker of fibrogenesis, our data are consistent with the
notion that signaling through TGFβ type I receptors such as
ALK5 contributes to the activation of HSC and hence
ALK4/5/7 inhibition would be expected to be an appropri-
ate treatment for liver fibrosis.
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Abbreviations
ALK activin linked kinase
CMV cytomegalovirus
CTGF connective tissue growth factor
FACS fluorescence activated cell sorter
HSC Hepatic stellate cells
HSPG heparan sulfate containing proteoglycans
PBS phosphate buffered saline
PKC protein kinase C
SEAP secreted enhanced alkaline phosphatase
TGFβ Transforming growth factor β
Introduction
Hepatic stellate cells (HSC) are the primary target of
fibrogenic stimuli in the diseased liver. During fibrogenesis,
HSC transition from a resting, vitamin A-rich phenotype to
a myofibroblastic phenotype characterized by loss of
vitamin A, expression of α-smooth muscle actin, and
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extracellular matrix production (Gressner and Bachem
1994; Pinzani 1995). Connective tissue growth factor
(CCN2), a cysteine-rich matricellular protein, regulates cell
adhesion, migration, proliferation, survival, and differen-
tiation via integrin- and heparan sulfate proteoglycan-
mediated adhesive signaling (Brigstock 1999; Leask and
Abraham 2006). CCN2 has fibrogenic properties in vitro
and is characteristically over-expressed in a wide variety of
fibrotic lesions, correlating with disease severity (Blom et
al. 2002; Dziadzio et al. 2005). Consistent with these
observations, CCN2 production is enhanced during the
progressive activation of primary HSC in vitro. Moreover,
CCN2 is further induced in HSC by the potent pro-fibrotic
cytokine TGF-β1 (Paradis et al. 1999; Williams 2000).
The molecular basis underlying CCN2 expression in
HSC is unknown. In other cell types, CCN2 expression is
controlled primarily at the transcriptional level; therefore
elements in its promoter are likely to contribute to its
expression in HSC (Blom et al. 2002). Previously, we have
analysed the regions in the CCN2 promoter required for its
induction in response to TGFβ and endothelin-1 in normal
fibroblasts and mesangial cells, and its constitutively
elevated activity in fibrotic scleroderma fibroblasts and
pancreatic cancer cells (Abraham et al. 2000; Holmes et al.
2001, 2003; Chen et al. 2006; Pickles and Leask 2007).
CCN2 induction in response to TGFβ in unactivated
fibroblasts and mesangial cells requires Smad and Ets
response elements in the CCN2 promoter [Holmes et al.
2001; Chen et al. 2002; Leask et al. 2003; Van Beek et al.
2006]. Smads generally regulate TGFβ signaling, and
Smad3 in particular is required for TGFβ to induce
CCN2 protein in fibroblasts (Holmes et al. 2001). The Ets
family of transcription factors are key regulators of
differentiation, hormone responses and tumorigenesis, and
Ets-1 in particular is required for TGFβ-induced CCN2
protein expression (Van Beek et al. 2006). Intriguingly,
CCN2 overexpression in scleroderma cells is independent
of TGFβ signaling via Smads and ALK5, but is dependent
on endothelin-1 by the endothelin A and B receptors
(Holmes et al. 2001; Chen et al. 2006; Shi-wen et al. 2007).
Moreover, CCN2 overexpression in pancreatic cancer cells
is independent of both TGFβ and endothelin-1, but is
dependent on activated ras/MEK/ERK (Pickles and Leask
2007). Thus although TGFβ can mediate the induction of
CCN2 in normal mesenchymal cells, overexpression of
CCN2 in pathological states has been shown thus far to be
independent of TGFβ.
Although CCN2 is induced by TGFβ and autocrine
TGFβ signaling is associated with HSC activation (Paradis
et al. 1999; Williams 2000), it is unclear whether TGFβ
signaling mediates the elevated CCN2 expression that
occurs during HSC activation. This issue is of particular
relevance given that the overexpression of CCN2 in other
activated cells is TGFβ independent. To address this
question, it is necessary to first identify the mechanism
underlying TGFβ-induced CCN2 expression in HSC and
then address whether this mechanism is of relevance to the
overexpression of CCN2 is activated HSC. The studies
reported here address these outstanding issues and provide
valuable insights into the fundamentl molecular mechanism
underlying HSC activation, and hence into how to control
hepatic fibrogenesis.
Materials and methods
CCN2 production in activated mouse HSC in vivo All
animal procedures were approved by Institutional Animal
Care and Use Committee of The Research Institute at
Nationwide Children’s Hospital, Columbus OH. Male 5-
week old Balb/c mice received daily i.m. injections (1 ml/
kg) of olive oil or a 1:1 ratio of carbon tetrachloride (CCl4):
olive oil for 1 week (Paradis et al. 1999). Mice (n=3 per
group) were sacrificed 2 days later and HSC were isolated
as described below. Freshly isolated HSC from CCl4- or
oil-treated mice were individually pooled, washed twice in
ice-cold PBS, and resuspended in binding buffer (10 mM
HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). The
samples were incubated at 4°C overnight with a 1:1000
dilution of polyclonal CCN2 antiserum raised in rabbits
against full-length recombinant CCN2. The samples were
incubated at 4°C overnight with a 1:1000 dilution of
polyclonal CCN2 antiserum raised in rabbits against full-
length recombinant CCN2 (Ball et al. 2003). This antibody,
termed “38B”, has been previously used for immunopre-
cipitation and Western blot and shows absolute specificity
for CCN2, with no cross-reactivity with other CCN proteins
(Ball et al. 2003 and data not shown). This antibody was
selected for cell sorting based on its superior performance
in the detection of CCN2-stably transfected Chinese
Hamster Ovary cells versus parental cells (Ball et al.
2003), as compared to either non-immune serum or six
other CCN2 antibodies produced in the investigators’
laboratory (D.R.B., unpublished observations). After sub-
sequent incubation of the HSC with FITC-conjugated anti-
rabbit IgG secondary antibody (1:1000; Invitrogen), the
cells were analysed on a FACSCalibur flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA). 104 cells
were tested in triplicate per sample and the data were
analysed with FlowJo software (Tree Star Inc., USA).
Isolation and culture of HSC Mouse livers were perfused in
situ with sequential 37°C treatments of heparin (100 U),
70 ml HBSS (without Ca2+/Mg2+), 0.5 mg pronase in 40 ml
DMEM/F12, and 5 mg collagenase IV in 70 ml DMEM/
F12. The livers were then removed, cut into pieces and
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agitated in 20 ml DMEM containing 0.2 mg DNAse at
37°C for 10 min. The resulting cell suspension was filtered
through a metal sieve and HSC were isolated based on
their buoyancy using an Optiprep gradient in which the
cells were collected in the 11% phase (Iredale 1992). Cell
purity (>95%) was determined using phase contrast
microscopy and UV excited fluorescence microscopy.
Oil-red staining was used to confirm the presence of
intracellular lipid droplets. Cell viability (>95%) was
determined by trypan blue exclusion For the oil or CCl4-
treated animals, HSC were isolated from all 3 animals in
each group and pooled for FACS analysis. For in vitro
culture experiments, HSC isolated from ten untreated mice
were resuspended and grown in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, Grand Island, NY,
USA) supplemented with 10% fetal calf serum, 100 U/ml
penicillin and 100 μg/ml streptomycin at 37°C. Cells used
were activated by 14 days of culturing and were placed
(3×105 cells/well) in 6-well tissue culture plates (Falcon;
Becton Dickinson, Franklin Lakes, NJ, USA) for further
analysis.
Reverse-transcriptase polymerase chain reaction Total
RNA from cultured mouse HSC was extracted at various
points using a TRIzol extraction kit (Gibco/BRL) according to
the manufacturer’s directions. First-strand cDNAwas synthe-
sized using 2 μg of RNA in 20 μl of reaction buffer by reverse
transcription using SuperScriptTM II RNAse H- Reverse
(Invitrogen) with oligo-dT(18)-primers. Complementary
DNA was amplified in a 50 μl total volume reaction
comprising 50 mM KCl, 20 mM Tris-HCl (pH 8.0), 10 mM
deoxynucleoside triphosphate (dNTP), 1.5 mM MgCl2, 1 U
Taq polymerase, and 10 pmol of the following polymerase







Amplification products were separated by electrophoresis
on 1% agarose gel containing ethidium bromide and
quantitated by scanning densitometry. The proportion of
specific gene product to β-actin product was used for
semiquantitive analysis which was determined using an
Alpha Innotech (San Leandro, CA, USA) imagaing system.
Transfections and DNA Constructs Cells were allowed to
grow for 24 h at 37°C. Cells were then transfected with
Fugene (Roche, Indianapolis, IN, USA) at a ratio of 3 μl:2 μg
DNA per well. Cells were transfected (1.75 μg/well) with
plasmids containing a CCN2 promoter containing DNA
spanning from nucleotides −805 to +17, or otherwise identical
constructs containing point mutations in either Smad or Ets
sites, fused to a secreted alkaline phosphatase (SEAP) reporter
gene (Abraham et al. 2000; Holmes et al. 2001; Leask et al.
2003; Van Beek et al. 2006). To control for transfection
efficiency cells were transfected with 0.25 μg of a
cytomegalovirus (CMV) promoter-β-galactosidase (CMV-
β-gal) reporter gene (Clontech, Palo Alto, CA, USA)
construct. Cells were allowed to grow for 48 h in 37°C.
Promoter assays were performed with a Phospha-Light kit
(Applied Biosystems, Foster City, CA, USA) according to
manufacturer’s protocol to detect SEAP reporter expression
and β-galactosidase expression was determined by a
Galacto-star kit (Applied Biosystems) according to manu-
facturer’s protocol. After adjusting the SEAP expression
values to reflect differences in transfection efficiencies as
determined by the β-galactoside expression values, adjusted
data was expressed as average values ± standard deviation of
at least three replicates and at least two independent trials.
Measurement of SEAP levels were obtained from an LMax
II 384 luminometer (Molecular Devices, Sunnyvale, CA,
USA) and SoftMax Pro 4.7.1 (Molecular Devices, Sunny-
vale CA, USA). Statistical tests were done using one-way
analysis of variance (ANOVA) and Tukey’s post-hoc test on
GraphPad.
Real time RT-PCR Assays were performed essentially as
previously described (Shi-wen et al. 2006; Kennedy et al.
2007; Pala et al. 2008). Cells were plated onto a six well
plate and allowed to grow for 24 h at 37°C. Cells were then
treated for 18 h with p38 MAP Kinase inhibitor SB203580,
MEK/ERK inhibitor U0126, TGFβ type I receptor (ALK4/
5/7) inhibitor SB431542 or the protein kinase C (PKC)
inhibitor bisindolmaleimide I (all Calbiochem, La Jolla,
CA, USA) at a concentration of 10 μM, except SB203580
which was used at 30 μM. Alternatively, cells were
serum-starved for 18 h prior to addition of actinomycin D
(15 μg/ml; Sigma) for 1 h. Cells were then treated in the
presence or absence of TGFβ to 6 h. RNA was harvested
using the Trozol (Invitrogen) and used for Real-Time RT-
PCR. 25 ng of RNA was reverse transcribed and amplified
using TaqMan Assays on Demand (Applied Biosystems) in a
15 μl reaction containing primers for TaqMan Human CCN2
(Applied Biosystems) and 6-carboxyfluroscein labeled
TaqManMGB probe. Reverse Transcriptase One-Step qPCR
Mastermix (Applied Biosystems) was added to samples and
the ABI Prism 7900 HT sequence detector (Perkin-Elmer-
Cetus, Vaudreuil, QC) was used according to manufacturer’s
instructions to detect amplified sequences. Samples were run
in triplicate, and expression values were standardized to
control values from GAPDH primers using the ΔΔCt
method (Livak and Schmittgen 2001). Statistical analysis
was done using one way ANOVA and Tukey’s post-hoc test
on GraphPad.
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Results
CCN2 production in mouse HSC is associated
with the activated phenotype
Since CCl4 causes liver injury and HSC activation in vivo,
this approach was used to explore CCN2 production by
mouse HSC. As shown in Fig. 1A, 92% of the HSC
isolated from the livers of CCl4-treated mice were CCN2-
positive whereas only 12% of the HSC from oil-treated
mice were CCN2-positive. Cultured HSC from non-treated
mice, contained cytoplasmic oil droplets on days 1–2 that
were visible under phase contrast and when stained with oil
red (Fig. 1B). By day 7, the droplets were no longer present
and the cells had undergone dramatic phenotypic changes,
appearing myofibroblastic and positive for αSMA expres-
sion (Fig. 1B and data not shown). Whereas freshly isolated
HSC exhibited very low expression of CCN2, the amount
of CCN2 mRNA increased as a function of time in culture
and was correlated with the autonomous transformation of
the cultured cells from a quiecent to activated phenotype
(Fig. 1C). Culture-induced HSC activation was also
associated with a concommitant increase in TGF-β expres-
sion (Fig. 1C). Collectively, these data showed that
activation of mouse HSC either in vivo or in vitro is
accompanied by elevated CCN2 production.
Basal and TGFβ-induced CCN2 expression in HSC
depends on transcription
To begin to probe the mechanism underlying the over-
expression of CCN2 in 14 day culture-activated HSC, we
assessed if autocrine TGFβ signaling could contribute to
this process. First, we ascertained whether transcriptional
regulation was likely to play a role. To perform this assay,
we serum-starved culture-activated HSC for 18 h, and cells
were treated in the presence or absence of TGFβ for 6 h.
Prior to addition of TGFβ, cells were treated for 1 h in the
presence or absence of actinomycin D, which blocks de
novo transcription. RNAs were harvested and subjected to
real-time PCR analysis to detect CCN2 mRNA. We found
that actinomycin D reduced basal CCN2 mRNA expression
in HSC (Fig. 2). Moreover, actinomycin D blocked TGFβ-
Fig. 1 CCN2 expression in activated mouse HSC. A FACS analysis
of CCN2-positive HSC from Balb/c mice receiving oil or CCl4
administration. HSC from each treatment group (n=3) were isolated
and a total of 10,000 cells were counted. The absolute number of
CCN2-positive cells is expressed as a percent of the total number
counted. B Characterization of cultured mouse HSC. Primary cultures
of mouse HSC on day 1 (a, b) or day 2 (c) were poorly spread and
contained oil droplets that stained with oil red. By day 7 (d), cells had
lost their oil droplets, had numerous cytoplasmic extensions, and were
αSMA-positive (not shown). Scale bars: 100 μm. C Reverse-
transcriptase PCR analysis of CCN2 or TGF-β mRNA expression in
mouse HSC during culture-induced activation. Data from each time
point shown in the inset were scanned and the signal intensity was
determined relative to that of β-actin. Data shown in A–C were
typical of three or more independent analyses
b
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induced CCN2 mRNA expression (Fig. 2). Thus transcrip-
tional regulation contributes to both basal and TGFβ-
induced CCN2 expression in HSC.
Basal and TGFβ-induced CCN2 expression in HSC
depends on ALK5 and Smad and Ets elements
in the CCN2 promoter
To begin to evaluate the hypothesis that TGFβ signaling
was responsible for the elevation of CCN2 expression
during HSC activation and to begin to determine which
promoter elements contributed to CCN2 overexpression in
HSC, we first ascertained the elements required for TGFβ-
induced CCN2 expression. HSC were transfected with
CCN2 promoter-SEAP reporter constructs containing
regions spanning between −805 to +17, or otherwise iden-
tical constructs in which Smad or Ets-1 sites were mutated
(Holmes et al. 2001; Leask et al. 2003; Van Beek et al. 2006;
Pickles and Leask 2007). Mutation of either the Smad or the
Ets-1 site significantly reduced the ability of the CCN2
promoter to respond to TGFβ (Fig. 3). Similarly, addition of
the TGFβ type I receptor (ALK4/5/7) inhibitor SB431542
blocked the ability of TGFβ to induce the CCN2 promoter.
Thus, the induction of the CCN2 promoter by TGFβ in HSC
required ALK5, and the Smad and Ets-1 sites.
To further investigate the specific promoter elements
involved in CCN2 overexpression in HSC and to probe the
involvement of autocrine TGFβ signaling in this process,
cells were transfected with CCN2 promoter-SEAP reporter
constructs containing the wild-type promoter sequence, or
point mutations to either the Smad or Ets-1 sites. Point
mutation of either the Smad or Ets-1 sites resulted in a
significant decrease in CCN2 promoter activity (Fig. 4).
Moreover, ALK5 inhibition also reduced activity of the
wild-type CCN2 promoter (Fig. 4). These results suggest
that activation of CCN2 expression in HSC is due at least in
part to activated TGFβ signaling.
To confirm these data and to determine which signaling
pathways contributed to CCN2 overexpression in HSC,
cells were treated with inhibitors to p38 (SB 203580, p38i),
MEK/ERK (U0126, ERKi), ALK4/5/7 (ALKi) or PKC
(bisindolmaleimide I, PKCi) at concentrations previously
demonstrated to selectively block action of the respective
targets. Real-time RT-PCR analysis determined that while
all inhibitors somewhat reduced CCN2 mRNA expression,
inhibition of either ALK5 and PKC resulted in a potent
(∼70%) reduction of CCN2 mRNA expression in HSC
(Fig. 5). Collectively, these data suggest that overexpres-
sion of CCN2 in HSC is due, at least in part, to autocrine
TGFβ signaling acting through ALK5 and the Smad and
Ets-1 sites in the CCN2 promoter.
Discussion
CCN2 is over-expressed in fibrotic diseases, including
those of the liver; indeed, CCN2 expression is a reliable
marker of the severity of fibrosis (Blom et al. 2002; Leask
and Abraham 2006). CCN2 appears to be a key contributor
to the fibrogenic phenotype of HSC in that CCN2 promotes
proliferation, adhesion, and collagen production of this cell
type through integrins and HSPGs (Gao et al. 2004; Gao
and Brigstock 2004). Through its role as a pro-adhesive
matricellular molecule, CCN2 can also amplify adhesive
signaling emanating from other pro-fibrotic ligands such as
fibronectin and TGFβ, and pro-inflammatory ligands such
as TNFα (Shi-wen et al. 2006; Chen et al. 2004, 2007).
Moreover, CCN2-deficient mouse embryonic fibroblasts
show impairment of a myriad of fibrogenic activity,
inclusing cell adhesion, matrix contraction, and gene
expression (Shi-wen et al. 2006; Kennedy et al. 2007; Pala
et al. 2008). Thus CCN2 is a promising marker of fibrosis
and also represents an excellent direct anti-fibrotic target
(Blom et al. 2002; Leask and Abraham 2006). As such,
Fig. 2 Transcription is required for basal and TGFβ-induced CCN2
mRNA in HSC. Culture-activated HSC were serum-starved for 18 h
prior to addition of actinomycin D (15 μg/ml, Act) for 1 h. Cells were
then incubated for 6 h in the presence or absence of TGFβ1 (4 ng/ml;
TGF). RNAs were harvested and subjected to real-time PCR analysis
with primers recognizing CCN2 or 18S. Relative CCN2 expression
was calcutated using the ΔΔCt method. Fold increase relative to
control, untreated samples is shown. Assays were performed in
triplicate. Standard deviation was less than 10%. Whereas TGFβ
increases CCN2 mRNA in HSC, this induction is blocked by
actinomycin D (TGF vs. TGF/Act,*p<0.05). Moreover, basal CCN2
expression is reduced in the presence of actinomycin D (control vs.
Act, *p<0.05)
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CCN2 is expressed in activated HSC and is induced by
TGFβ in this cell type. However, until this report there was
no proposed mechanism for CCN2 induction and over-
expression in activated HSC. Moreover, although TGFβ
can mediate the induction of CCN2 in normal mesenchymal
cells, TGFβ through the Smad/ALK5 pathway does not
appear to mediate the overexpression of CCN2 in activated
myofibroblasts (Holmes et al. 2001; Chen et al. 2006). As
there is currently no sufficient treatment for liver fibrosis,
obtaining a greater understanding of the mechanisms
underlying HSC activation, such as the mechanism under-
lying the overexpression of CCN2, is crucial in order to
identify novel potential drug targets and to evaluate the
possibility of targeting the TGFβ receptor ALK5 to combat
fibrosis.
In this report we probe the mechanism underlying the
regulation of CCN2 expression in HSC. Basal and TGFβ-
induced expression in activated HSC relied at least on part
on gene transcription, as basal CCN2 mRNA expression
was reduced and TGFβ-induced CCN2 mRNA expression
was ablated in the presence of actinomycin D. It has been
shown previously in normal fibroblasts and mesangial cells
that CCN2 is induced by TGF-β acting through the Smad
3/4 pathway and an Ets element (Leask et al. 2003; Chen et
al. 2002; Van Beek et al. 2006). In this report we show that
such a mechanism also operates in HSC, in that the
increased activity of the CCN2 promoter in response TGFβ
was diminished by mutation of the Smad and Ets elements.
We extend our data in other cell systems to show that, in
HSC, ALK4/5/7 inhibition can block the TGFβ-induction
of the CCN2 promoter and mRNA. For the first time,
however, we present data indicating that activated TGFβ
signaling can contribute to CCN2 overexpression in
myofibroblasts by showing that in activated HSC, mutation
of the Ets and Smad elements and addition of an ALK4/5/7
Fig. 4 Activity of CCN2 promoter constructs in HSC: elements
required for basal promoter activity HSC (14 days in culture) were
seeded into 12 well plates and transfected with CCN2 promoter/SEAP
reporter constructs, as described in Methods. SEAP reporter activity
(after adjustment for differences among samples in transfection
efficiency as revealed by cotransfected CMV-β-gal reporter construct)
was calculated. Experiments were performed in quadruplicate, at least
twice. Relative light units (averages ± standard deviation) are shown.
Mutation of the Smad or Ets element or addition of ALK4/5/7
inhibitor also reduced basal CCN2 promoter activity (*p<0.05)
Fig. 5 The effect of signal transduction inhibitors on CCN2 mRNA
expression in HSC. HSC (14 days in culture) were Incubated for 24 h
with: DMSO (control); ALK4/5/7 inhibitor (Alki, 10 μM); the MEK
inhibitor U0126 (meki, 10 μM); the p38 Inhibitor SB 203580 (p38i,
30 μM) or the PKC inhibitor Bisindolylmaleimide I (PKCi, 10 μM).
RNAs were harvested and subjected to real time PCR analysis with
primers recognizing CCN2 and 18S. Relative expression (to 18S) was
calculated and adjusted to control (DMSO) alone treated values
usingthe ΔΔCt method. Average expression values (three replicates)
is shown. The standard deviation was less that 5% (*p<0.05).
Blocking the TGFβ type I ALK4/5/7 receptor (Alki) and PKC (PKCi)
potently reduces basal CCN2 mRNA expression
Fig. 3 Activity of CCN2 promoter constructs in HSC: elements required
for TGFβ response. HSC (14 days in culture) were seeded into 12 well
plates and transfected with CCN2 promoter/SEAP reporter constructs, as
described in Methods. Experiments were performed in quadruplicate, at
least twice. SEAP reporter activity (after adjustment for differences
among samples in transfection efficiency as revealed by cotransfected
CMV-β-gal reporter construct) was calculated. Fold increase in response
to TGFβ for each consctruct and treatment was then calculated. Average
fold increase ± standard deviation is shown. Post-transfection, cells were
serum-starved for 18 h prior to addition of TGFβ1 (4 ng/ml) for an
additional 24 h. When indicated, cells were pre-treated for 45 min with
10 μM ALK4/5/7 inhibitor prior to addition of TGFβ1. Whereas TGFβ
induced a promoter/reporter construct contaning nucleotides spanning
−805 to +17 CCN promoter (FL), mutation of the Smad or Ets element
within this promoter fragment or addition of ALK4/5/7 inhibitor (ALKi)
blocked this induction (*p<0.05)
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inhibitor reduced the activity of the CCN2 promoter in this
cell type. Moreover, ALK4/5/7 inhibition reduced CCN2
mRNA expression in this cell type. Collectively, these
results support the notion that activated TGFβ signaling
may contribute to HSC activation. Conversely, in sclero-
derma fibroblasts in which CCN2 overexpression is TGFβ/
Smad/ALK5-independent but ET-1 dependent and in
pancreatic cancer cells CCN2 expression is independent
of both TGFβ and ET-1 (Holmes et al. 2001; Chen et al.
2006; Pickles and Leask 2007). Our results indicate that,
CCN2 overexpression in HSC can be antagonized by ALK4/
5/7 inhibition and support the notion that activated TGFβ
signaling via the ALK4/5/7 receptor may play a key role HSC
activation. Given that CCN2 overexpression is a faithful
marker of the fibrogenic phenotype, ALK4/5/7 inhibitionmay
be an appropriate method of attenuating liver fibrosis.
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